Advanced Miniature In-Line Blood Gas Analyzer Launched in Europe
|
By LabMedica International staff writers Posted on 31 Mar 2015 |

Image: The miniature Proxima Sensor is integrated into a patient’s arterial line to be used for directly monitoring blood gases and electrolytes over a 72 hour period as many times as required (Photo courtesy of Sphere Medical).

Image: The new Proxima in-line patient-dedicated point-of-care blood gas analyzer incorporates Proxima Sensor (in foreground) and dedicated bedside monitor (Photo courtesy of Sphere Medical).
A CE-marked patient-dedicated system, presented at ISICEM 2015, delivers point-of-care testing (POCT) by enabling critical care staff to obtain rapid and frequent laboratory-accurate arterial blood gas measurements without leaving the patient’s bedside, facilitating effective and timely clinical decisions.
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Latest Hematology News
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Channels
Molecular Diagnostics
view channel
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read more
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Chemotherapy selection for breast cancer is challenged by heterogeneous tumor responses. Conventional chemosensitivity assays can be slow, require large sample volumes, and struggle with complex biological... Read more
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








